Clinical Trial Update: Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN) [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety and efficacy of filgotinib plus lanraplenib in adults with lupus membranous nephropathy has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Membranous Nephropathy

Drugs mentioned

• Filgotinib (filgotinib)
• lanraplenib (lanraplenib)

Snippet

Sponsor: Gilead Sciences | Conditions: Lupus Membranous Nephropathy | Phase 2 | Status: COMPLETED | Results posted: 2020-05-18